Long-term use of Bonviva for the treatment of postmenopausal osteoporosis: new evidence
Osteoporosis is a disease of great social importance. Its treatment is a complicated problem and it is associated with low compliance and a risk for adverse reactions. Ibandronate belongs to a group of bisphosphonates. The performed trials have proven the efficacy of its two formulations (a tablet o...
Saved in:
| Main Authors: | Olga Borisovna Yershova, K Yu Belova, A V Nazarova |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2012-03-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/402 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Comparative pharmacoeconomic analysis of the use of Bonviva® (ibandronat) to prevent fractures in postmenopausal osteoporosis
by: E A Pyadushkina, et al.
Published: (2012-12-01) -
The experience of the parenteral form of ibandrinic acid administration in different clinical situations of treatment of postmenopausal osteoporosis
by: L. A. Marchenkova, et al.
Published: (2021-06-01) -
The use of bisphosphonates for the treatment and prevention of osteoporosis
by: O. A. Nikitinskaya, et al.
Published: (2022-08-01) -
BISPHOSPHONATE TREATMENT AND ESOPHAGEAL DISEASE
by: Andrei Evgenyevich Karateyev
Published: (2010-09-01) -
EFFECT OF IBANDRONATE ON RISKS FOR VERTEBRAL AND NONVERTEBRAL FRACTURES IN POSTMENOPAUSALOSTEOPOROSIS (A REVIEW OF CLINICAL TRIALS)
by: Evgeni Germanovich Zotkin
Published: (2010-06-01)